CORRECTING and REPLACING Testgene Launches ArrayAssist® Exon and ArrayAssist® Expression Software For Mac® OS X

SAN FRANCISCO--(BUSINESS WIRE)--Phone number for Diane Tester should read: 123-456-7980 (instead of 858/555-6441).

The updated release reads: 

TESTGENE LAUNCHES ARRAYASSIST® EXON AND ARRAYASSIST® EXPRESSION SOFTWARE FOR MAC® OS X

Testgene Corporation (NASDAQ:TEST), a leading developer, manufacturer and marketer of specialized life science research and diagnostic products, today announced the launch of its ArrayAssist® Exon and ArrayAssist® Expression software for Mac® OS X version 10.4 "Tiger." The ArrayAssist line of software products consists of powerful yet extremely intuitive packages that enable life scientists to analyze the new generation of Affymetrix GeneChip® Exon Arrays and data from other microarray platforms.

“In designing the ArrayAssist and PathwayArchitect™ software, we put tremendous effort into optimizing the user experience for the research scientist,” said David Anyone, Senior Vice President of Marketing at Testgene. “Apple has always been a favorite platform for scientists, so it was a natural decision to offer the latest in Affymetrix data analysis to the Mac community and to launch at Macworld.”

“Apple is traditionally strong in the research, science and engineering fields and the popularity of Tiger continues to drive exciting growth in these segments,” said Ron Okamoto, Apple’s vice president of Worldwide Developer Relations. "We're excited about the discoveries researchers will be able to make using Tiger and the ArrayAssist applications to analyze Affymetrix's new GeneChip Exon Arrays."

“We are very pleased that Testgene is offering ArrayAssist Expression and ArrayAssist Exon software to our customers," said John Blume, Ph.D., Vice President of Expression at Affymetrix. "The GeneChip Exon Arrays offer an unmatched platform for biological discovery and, with its biology-focused workflow, the ArrayAssist Exon software makes advanced analysis of this data very straightforward.”

About ArrayAssist

The ArrayAssist Exon software is capable of processing Affymetrix GeneChip Exon Arrays, from raw .CEL data through primary expression and quality analysis to advanced gene-level and exon-level analysis. It has a comprehensive suite of tools to examine both transcriptional and splicing regulation using the exon arrays.

The ArrayAssist platform line provides easy to use, biology-focused workflows while offering a full spectrum of advanced analytical features such as multi-way ANOVA, non-parametric statistical tests, classifiers for machine learning-based prediction and sophisticated, interactive visualization options. Both packages are fully integrated with Testgene’s recently launched PathwayArchitect systems biology pathway analysis software. In addition to Mac OS X, the ArrayAssist Expression and ArrayAssist Exon software are both compatible with Windows® and Linux®.

About Testgene Corporation

Testgene is a developer, manufacturer and marketer of specialized life science research and diagnostic products. The Company's life science research unit supports advances in science by inventing, manufacturing and distributing products that simplify, accelerate and improve research. These products are used throughout the academic, industrial and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology. The Company's diagnostic unit develops and manufactures products for urinalysis, and high quality automated instrument and reagent systems that use blood samples to test for more than 1,000 different allergies and autoimmune disorders. In addition, by combining its expertise in diagnostics and molecular biology, as well as its experience with FDA regulatory procedures, the Company is pursuing opportunities to expand its product portfolio to include molecular diagnostic kits and instrumentation. More information is available at http://www.Testgene.com.

Safe Harbor Statement

Certain statements in this news release that are not historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements. Testgene generally identifies forward- looking statements by using words like "believe," "intend," "target," "expect," "estimate," "may," "should," "plan," "project," "contemplate," "anticipate," "predict" or similar expressions. You can also identify forward- looking statements by discussions of strategies, plans or intentions. Such forward- looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results of Testgene to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Among the important factors that could cause actual results to differ materially from those contained in or implied by the forward- looking statements are risks associated with the company's inability to sufficiently anticipate market needs and develop products and product enhancements that achieve market acceptance, including molecular diagnostic testing kits and related products, the company's ability to compete effectively in the diagnostics and life sciences research markets, variability of the company's quarterly revenues and operating results, the failure of the company to retain key employees, the company's ability to obtain additional debt or equity financing, the possibility of declining sales due in part to a reduction in research and development budgets or government funding, the company's ongoing ability to protect its own intellectual property rights and to avoid violating the intellectual property rights of third parties, extended manufacturing difficulties and currency fluctuations. For more information about these and other factors that could cause actual results to differ materially from those contained in or implied by the forward- looking statements please see "Factors that May Affect Future Results" included in Testgene's Annual Report on Form 10-K for the year ended December 31, 2004 and in other reports filed by Testgene from time to time with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q.